144 ·Filed Aug 10, 2026

CMPS

COMPASS Pathways plc
NEUTRAL
Impact 3/10
Horizondays Processed1mo ago SEC0001959173-26-005811
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine Form 144 filing by a former director for a modest share amount. No immediate trading action is warranted. Monitor for any actual Form 4 filings reflecting completed sales, but this filing alone does not signal insider concern about the company's prospects.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled — T+20d
CMPS ▲ +6.53% at T+20d
NEUTRAL call ✓ call won +6.53% · α vs SPY +7.44% · entry $13.18 → $14.04
Next anchor: T+60d in 5w
Latest observation: T+37 -25.72% FF3 residual α
Entry anchored
Aug 10, 01:26 PM ET
via 1-min bar
T+1d
+1.52%
call +1.52% · α +1.84%
$13.38
settled 7w ago
T+5d
+4.10%
call +4.10% · α +4.14%
$13.72
settled 7w ago
T+20d
+6.53%
call +6.53% · α +7.44%
$14.04
settled 24d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Former director Annalisa Jenkins filed a Form 144 notice of intent to sell 26,000 American Depositary Shares of COMPASS Pathways, with an estimated aggregate market value of approximately $345,799. The shares were acquired via stock option exercise on the same day. While the filing signals a planned sale by a former board member, the amount is modest relative to the company's $1.9B market cap and Jenkins' remaining holdings (83,771 ADSs still held). No material negative signal is warranted from this routine diversification sale by a non-executive former director.

Key Facts

  • Former director Annalisa Jenkins filed Form 144 to sell 26,000 ADSs of COMPASS Pathways.
  • Estimated aggregate market value of the proposed sale is $345,799.36.
  • Shares were acquired via stock option exercise on August 10, 2026.
  • Jenkins still holds 83,771 ADSs after the proposed sale.
  • The sale represents a small fraction of the company's $1.9B market cap.

Financial Impact

Proposed sale of 26,000 ADSs valued at ~$345,799, representing ~0.02% of market cap.

dilution

Risk Factors

  • The sale may still be completed, adding modest supply to the market.
  • Former director sales can sometimes precede broader insider selling patterns.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (24 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-005811
Document: 0001959173-26-005811-index.html0001959173-26-005811
Document: 0001959173-26-005811.txt0001959173-26-005811
4 reports for CMPS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CMPS — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
144
NEUTRAL ★ 3/10
$13.18 $14.04▲ +6.53%▲ +7.44%$11.93 (−9.48%)
Aug 5, 2026
8w ago
8-K
NEUTRAL ★ 5/10
$13.58 $13.23▼ −2.58%▼ −1.98%$11.93 (−12.15%)
Jul 7, 2026
12w ago
8-K
NEUTRAL ★ 3/10
$12.99 $11.25▼ −13.39%▼ −14.73%$11.93 (−8.16%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 5/10
$11.41 $13.60▲ +19.19%▲ +17.30%$11.93 (+4.56%)
Showing 4 of 4

US Market Status

Market Open — Closes in 3h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access